Skip to main content

Christophe Lo Bianco, PhD

Location: Sweden

Christophe Lo Bianco, PhD, obtained a doctorate in Neuroscience & Gene therapy from the Swiss Federal Institute of Technology and Gene Therapy Center, Lausanne, in Switzerland under the direction of Prof. Patrick Aebischer. Dr. Lo Bianco developed a genetic rat model of Parkinson's disease based on the nigral injection of viral vectors overexpressing human alpha-synuclein. This model is characterized by a progressive loss of dopaminergic neurons in the substantia nigra associated with the presence of alpha-synuclein-positive inclusions. In this animal model, he first evaluated the ability of glial cell line-derived neurotrophic factor (GDNF) in protecting dopamine neurons from the alpha-synuclein toxicity. Surprisingly, although GDNF has been documented extensively as one of the most potent survival-promoting factors for dopamine neurons, it did not have any effect in the alpha-synuclein overexpression model. Recently, Dr. Lo Bianco published the first in vivo demonstration of a novel gene therapy for Parkinson's disease. Using a recombinant lentiviral vector that encoded the parkin gene, he showed that the overexpression of parkin blocks alpha-synuclein induced neurodegeneration of dopamine neurons. Dr. Lo Bianco is now evaluating the neuroprotective properties of chaperones and small molecules in blocking the neurodegeneration observed in the lentiviral-based model of PD. His major scientific interest concerns the mechanisms leading to neurodegeneration in human disorders as PD in order to define more efficient therapies.

Associated Grants

  • Understanding and Modeling the Complexity of Sporadic Parkinson's Disease: Genetic and Environmental Factors


  • Understanding the Role of Glucocerebrosidase in Parkinson's Disease Pathogenesis: Toward a New Genetic Model of Sporadic PD


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.